Retro Biosciences was last valued at $1.8B (post-money). It comes from the Series B of May 2026. The company is private, so there is no listed share price.
1 valuation. The latest, $1.8B post-money, was set by the Series B in May 2026.
A private valuation is the price agreed in one transaction. The Retro Biosciences valuation of $1.8B is a post-money figure from the Series B dated 22 May 2026 .
The valuation holds until the next priced round or secondary sale. A private company founded in 2021 with roughly 50 people has no daily price and no order book between rounds.
The last valuation is $1.8B.
Lead investors for each round are in the funding timeline.
The closest biotechnology peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Retro Biosciences is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
